Eurofins Scientific SE Stock
Stocks
ERF
FR0014000MR3
Biotechnology & Medical Research
OTC Markets Traded|
Real-time
Euronext Paris
06:52:59 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 75.28 EUR | +0.99% |
|
-2.69% | +20.64% |
| 03:27am | Eurofins Completes Sale of MET Labs Business | MT |
| 10-01 | UL Solutions Completes Acquisition of Eurofins' Electrical, Electronics Business | MT |
| Market Cap | 12.94B 14.57B 12.1B 11.03B 20.76B 1,403B 21.05B 146B 56.67B 714B 54.7B 53.51B 2,295B | P/E 2026 * |
24.9x | P/E 2027 * | 19.6x |
|---|---|---|---|---|---|
| Enterprise Value | 16.31B 18.36B 15.25B 13.9B 26.16B 1,768B 26.52B 184B 71.41B 900B 68.93B 67.43B 2,891B | EV / Sales 2026 * |
2.16x | EV / Sales 2027 * | 2.01x |
| Free-Float |
60.39% | Yield 2026 * |
1.08% | Yield 2027 * | 1.22% |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ERF | Real-time | |
CBOE
| Real-time | ||
|
OTC Markets
| ERFSF | Delayed | |
|
Tradegate
| ESF0 | Real-time | |
|
Boerse Muenchen
| ESF0 | Real-time | |
|
Deutsche Boerse AG
| ESF0 | Delayed | |
|
Xetra
| ESF0 | Delayed | |
|
London S.E.
| 0MV5 | Delayed | |
|
CBOE
| 0MV5 | Real-time | |
|
Börse Stuttgart
| ESF0 | Delayed | |
|
Wiener Boerse
| ESF | End-of-day quote | |
|
Borsa Italiana
| 4ERF | End-of-day quote |
Last Transcript: Eurofins Scientific SE
| 1 day | +0.99% | ||
| 1 week | -2.69% | ||
| Current month | +0.37% | ||
| 1 month | +3.44% | ||
| 3 months | +8.88% | ||
| 6 months | +12.53% | ||
| Current year | +20.64% |
| 1 week | 73.3 |  | 78.92 |
| 1 month | 68.38 | | 79.22 |
| Current year | 56.84 | | 79.22 |
| 1 year | 54.86 | | 79.22 |
| 3 years | 39.47 | | 79.22 |
| 5 years | 39.47 | | 118.12 |
| 10 years | 29.82 | | 127.68 |
| Manager | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CEO | Chief Executive Officer | 63 | 1986-12-31 |
Laurent Lebras
DFI | Director of Finance/CFO | - | 2014-12-31 |
Christian Wurst
PRN | Corporate Officer/Principal | 54 | 2019-09-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Gilles Martin
CHM | Chairman | 63 | 1986-12-31 |
Yves-Loïc Martin
BRD | Director/Board Member | 60 | 2014-12-31 |
Valérie Hanote
BRD | Director/Board Member | 60 | 1989-12-31 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 4/27/26 | Buy | 700 | 0.0004% | |||
| 4/19/26 | Sell | Chief Financial Officer | 3,000 | 0.0016% | ||
| 4/19/26 | Exercice | Executive/Senior Manager | 700 | 0.0004% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.99% | -2.69% | +19.80% | +43.83% | 14.57B | |
| +4.16% | +3.04% | +49.37% | +94.17% | 74.41B | |
| -0.90% | -1.35% | +24.67% | +78.54% | 59.26B | |
| +1.25% | -0.42% | +4.50% | +34.79% | 47.14B | |
| -3.02% | -5.20% | +27.94% | +32.51% | 42.91B | |
| +0.31% | +3.02% | +348.95% | +643.82% | 44.13B | |
| -1.96% | -0.33% | +7.04% | +99.46% | 40.79B | |
| +3.32% | +3.49% | +10.10% | +51.23% | 30.77B | |
| -2.68% | +2.92% | +29.63% | +22.72% | 29.31B | |
| -4.86% | -10.66% | -26.27% | +330.06% | 23.71B | |
| Average | -0.34% | -0.88% | +49.57% | +143.12% | 40.7B | |
| Weighted average by Cap. | +0.10% | -0.45% | +56.70% | +142.19% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.53B 8.48B 7.05B 6.42B 12.09B 817B 12.25B 85.24B 33B 416B 31.85B 31.16B 1,336B | 7.94B 8.94B 7.43B 6.77B 12.74B 861B 12.92B 89.85B 34.78B 438B 33.57B 32.84B 1,408B |
| Net income | 531M 598M 496M 452M 852M 57.55B 863M 6.01B 2.33B 29.31B 2.24B 2.2B 94.14B | 660M 743M 617M 562M 1.06B 71.51B 1.07B 7.46B 2.89B 36.42B 2.79B 2.73B 117B |
| Net Debt | 3.37B 3.79B 3.15B 2.87B 5.4B 365B 5.47B 38.08B 14.74B 186B 14.23B 13.92B 597B | 3.03B 3.42B 2.84B 2.59B 4.87B 329B 4.93B 34.32B 13.29B 167B 12.82B 12.55B 538B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-10-02 | €75.28 | +0.99% | 144,038 |
| 26-10-01 | €74.54 | -0.61% | 496,921 |
| 26-09-30 | €75.00 | -1.57% | 653,261 |
| 26-09-29 | €76.20 | -3.20% | 305,088 |
| 26-09-28 | €78.72 | +1.76% | 190,736 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ERF Stock
Select your edition
All financial news and data tailored to specific country editions
